Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZODIAC: Zibotentan and Dapagliflozin in T2D with Albuminuria
NCT05570305Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of zibotentan in chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change from baseline in albuminuria at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05570305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570305.